As COVID-19 hospitalizations continue to surge around the world, other dangerous infections may also make patients sick. Candida Auris, Reported by National Geographic..
Super bug yeast It can infect ears and open wounds, enter the bloodstream, and cause severe systemic infections. According to the US Centers for Disease Control and Prevention (CDC). Yeast adheres to the surface and spreads easily in healthcare environments, especially among patients with catheters and other tubes entering the body.
Well, the initial data is COVID-19 (new coronavirus infection) (# If there is no character limit, add parentheses when it first appears Hospital patients may also be on the rise C. Auris Case, according to a National Geographic report. In particular, the United States has already reported 1,272 fungal infections this year. According to the CDC — This is about 400% more than the number of Cases reported throughout 2018, The latest year with available data. Given that the ongoing pandemic disrupted the surveillance systems used to track the fungal epidemic, the number of cases in 2020 could be even higher than reported.Other types of fungi Candida The genus is very similar C. AurisTherefore, doctors can only identify yeast by using specialized laboratory tests.
Relation: 20 of the worst fads and pandemics ever
“Unfortunately there was a place where we saw the resurrection C. auris,“Dr. Tom Chiller, head of the CDC’s fungal disease division, told National Geographic that it’s hard to get rid of because it has a store in one place.”
According to the CDC, “Patients C. Auris For a long time, that is, the fungus can stay on them skin “And without necessarily causing overt symptoms C. Auris It may stay on the surface of the medical environment. Super bugs are also notorious for being difficult to treat. C. Auris There are several varieties of yeast that show resistance to different classes of yeast AntibioticsIn particular, many varieties studied showed resistance to common antifungal fluconazole, and some showed resistance to amphotericin B, a secondary antifungal drug that could be given if the first antibiotic failed. National Geographic reported showing. If second-line treatment also fails due to drug resistance, doctors may have to resort to treating the patient with third-line treatment.
The most well-known variant of C. Auris Although it can be treated with a tertiary antifungal agent called equinocandin, these treatments are not readily available in all countries and some variants of yeast are found in all three classes of antifungal agents. Shows resistance. Thousands of cases have been reported worldwide since yeast was identified in 2009. According to authorities, many of these people were suffering from other serious illnesses at the same time, but about 30% to 60% of people infected with fungi around the world died.
Dr. Anuradha Chowdhary, a professor of medical mycology at the Vallabhbhai Patel Chest Institute at the University of Delhi, told National Geographic that patients with COVID-19 need to be screened on a regular basis. C. AurisTo accurately track infection rates and identify any antibiotic treatments that may help the affected patient recover.
“If we don’t identify it, we don’t know if the patient is dead from COVID-19 or another infection,” Chowdhary said. But “if it’s drug resistant, how do we treat it?” She added.
For certain variants of C. Auris The CDC resists all three classes of antifungal drugs and states that “treatment of infections may require high doses of multiple classes of antifungal drugs.” the study suggest The simultaneous use of multiple classes of antifungal agents has an additive effect and may help to defeat yeast resistance to individual agents, but this needs to be confirmed with more data.
You can learn more about C. Auris so National Geographic..
Originally published in Live Science.